Immunosuppressive and Cytotoxic Therapy: Pharmacology, Toxicities, and Monitoring

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Seminars in Respiratory and Critical Care Medicine

• Publication date

  2011-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0031-1279831PMID 21674420
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Rituximab-induced interstitial lung disease].

  2013cited by this paper
• Pharmacological Therapy for Wegener’s Granulomatosis

  2012cited by this paper
• The pulmonary vasculitides.

  2012influential reference
• Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy

  2011cited by this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

  2011cited by this paper
• Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?

  2010cited by this paper
• The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases.

  2010cited by this paper
• Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection

  2010cited by this paper
• Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

  2010cited by this paper
• Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases.

  2010influential reference
• Lymphoma, rheumatoid arthritis, and TNFalpha antagonists.

  2010cited by this paper
• Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin.

  2010cited by this paper
• Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.

  2010cited by this paper
• Rituximab in ANCA-associated disease.

  2010cited by this paper
• Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.

  2010cited by this paper
• Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis.

  2010cited by this paper
• The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.

  2010influential reference
• TNF-α antagonists beyond approved indications: stories of success and prospects for the future.

  2010cited by this paper
• Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

  2010cited by this paper
• Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis

  2010cited by this paper
• Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

  2010influential reference
• The pulmonary vasculitides.

  2010cited by this paper
• Rituximab (Rituxan)

  2010influential reference
• Faculty Opinions recommendation of Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

  2010cited by this paper
• Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases.

  2010influential reference
• Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials

  2010influential reference
• Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial

  2010cited by this paper
• Advances in the use of biologic agents for the treatment of systemic vasculitis

  2009cited by this paper
• Sustained improvement of vascular endothelial function during anti‐TNFα treatment in rheumatoid arthritis patients

  2009cited by this paper
• Treatments for psoriasis and the risk of malignancy.

  2009cited by this paper
• Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier.

  2009cited by this paper
• Rituximab-induced acute thrombocytopenia: a case report and review of the literature

  2009cited by this paper
• B‐cell depletion with rituximab for refractory head and neck Wegener’s granulomatosis: a cohort study

  2009cited by this paper
• Successful treatment of hypertrophic pachymeningitis in refractory Wegener’s granulomatosis with rituximab

  2009cited by this paper
• Adverse effects of therapy for ANCA-associated vasculitis.

  2009cited by this paper
• Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis

  2009cited by this paper
• Mycophenolate Mofetil Decreases Acute Rejection and may Improve Graft Survival in Renal Transplant Recipients When Compared with Azathioprine: A Systematic Review

  2009cited by this paper
• Mycophenolate mofetil as maintenance therapy in patients with vasculitis and renal involvement.

  2009cited by this paper
• PERSISTENT ANTIBODY DEPLETION AFTER RITUXIMAB IN THREE CHILDREN WITH AUTOIMMUNE CYTOPENIAS

  2009cited by this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

  2009cited by this paper
• A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

  2009cited by this paper
• Prompt plasmapheresis successfully rescue pulmonary-renal syndrome caused by ANCA-negative microscopic polyangiitis

  2009cited by this paper
• Neurological complications of biologic therapy in psoriasis: a review.

  2009cited by this paper
• Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis.

  2009cited by this paper
• Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection

  2009cited by this paper
• Clinical outcomes in sarcoidosis after cessation of infliximab treatment

  2009cited by this paper
• Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients

  2009cited by this paper
• Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis

  2009cited by this paper
• Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

  2009cited by this paper
• Infectious complications of biologic agents.

  2009cited by this paper
• Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

  2009influential reference
• A review of the current use of rituximab in autoimmune diseases.

  2009cited by this paper
• Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

  2009cited by this paper
• Malignancies following long-term azathioprine treatment in chronic liver disease. A report from the Copenhagen Study Group for Liver Diseases.

  2008cited by this paper
• B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period

  2008cited by this paper
• The epidemiology of glucocorticoid-associated adverse events

  2008cited by this paper
• Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients

  2008cited by this paper
• Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.

  2008cited by this paper
• Drug-induced lupus due to anti-tumor necrosis factor alpha agents.

  2008cited by this paper
• Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.

  2008influential reference
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

  2008cited by this paper
• Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell Development

  2008cited by this paper
• Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

  2008cited by this paper
• Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs.

  2008cited by this paper
• Malignancy and biologic therapy in rheumatoid arthritis

  2008cited by this paper
• Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

  2008influential reference
• Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis.

  2008cited by this paper
• Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis.

  2008influential reference
• Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients.

  2008influential reference
• Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement.

  2008cited by this paper
• Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma

  2008cited by this paper
• Infliximab-induced disseminated histoplasmosis in a patient with Crohn's disease

  2008cited by this paper
• Malignancies and cyclophosphamide exposure in Wegener's granulomatosis.

  2008cited by this paper
• Limited Utility of Rapamycin in Severe, Refractory Wegener’s Granulomatosis

  2008cited by this paper
• Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma

  2008cited by this paper
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

  2008cited by this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

  2008cited by this paper
• Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?

  2008cited by this paper
• Drug-Induced Lupus due to Anti-Tumor Necrosis Factor α Agents

  2008cited by this paper
• Defining Algorithms for Efficient Therapeutic Drug Monitoring of Mycophenolate Mofetil in Heart Transplant Recipients

  2008cited by this paper
• Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV‐infected CD20‐positive B‐cell lymphoma undergoing rituximab combination chemotherapy

  2008cited by this paper
• Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment.

  2008cited by this paper
• EULAR recommendations for the management of primary small and medium vessel vasculitis

  2008cited by this paper
• Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study.

  2007cited by this paper
• Infliximab for the therapy of chronic sarcoidosis

  2007cited by this paper
• Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients.

  2007cited by this paper
• What effects might anti-TNFα treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFα in cardiovascular pathophysiology

  2007cited by this paper
• Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis.

  2007cited by this paper
• Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)

  2007cited by this paper
• Two cases of refractory Wegener's granulomatosis successfully treated with rituximab.

  2007cited by this paper
• Infectious complications of monoclonal antibodies used in cancer therapy

  2007cited by this paper
• Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients

  2007cited by this paper
• Rituximab‐induced interstitial lung disease

  2007cited by this paper
• Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis.

  2007cited by this paper
• Navigating the maze of hepatitis B treatments.

  2007cited by this paper
• Interstitial Pneumonitis and Alveolar Hemorrhage Complicating Use of Rituximab

  2007cited by this paper
• Suggested guidelines for patient monitoring: hepatic and hematologic toxicity attributable to systemic dermatologic drugs.

  2007cited by this paper
• Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis

  2007cited by this paper
• Pneumocystis jiroveci (carinii) Pneumonia After Infliximab Therapy: A Review of 84 Cases

  2007cited by this paper
• Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases

  2007cited by this paper

• Neutrophils in cancer: from biology to therapy

  2024cites this paper
• Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Evolving Concepts in Treatment

  2018cites this paper
• Cardiac Involvement in Sarcoidosis: Evolving Concepts in Diagnosis and Treatment

  2017cites this paper
• Interferon-α for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center Retrospective Observational Cohort Study

  2017cites this paper
• Idiopathic Pulmonary Fibrosis: Epidemiology, Clinical Features, Prognosis, and Management

  2016cites this paper
• Novel Acylguanidine-Based Inhibitor of HIV-1

  2016cites this paper
• The CD4 Lymphocyte Count is a Better Predictor of Overall Infection Than the Total Lymphocyte Count in ANCA-Associated Vasculitis Under a Corticosteroid and Cyclophosphamide Regimen

  2015cites this paper
• Phosphorus-32, a Clinically Available Drug, Inhibits Cancer Growth by Inducing DNA Double-Strand Breakage

  2015cites this paper
• Cardiac Involvement in Sarcoidosis: Evolving Concepts in Diagnosis and Treatment

  2014cites this paper
• Neues in der Immunsuppression von Vaskulitiden

  2012cites this paper
• [32P]ATP inhibits the growth of xenografted tumors in nude mice

  2012cites this paper
• Kortikosteroidy a imunosupresiva v chronické léčbě

  2011cites this paper
• Immune Mediated Diseases and Immune Modulation in the Neurocritical Care Unit

  2011cites this paper